ArticleFrontiers in public health2025
TRAF2 regulates the progression of pulmonary fibrosis through β-catenin-Snail signaling pathway.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rubiadin-1-methyl ether alleviates bleomycin induced pulmonary fibrosis.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pulmonary fibrosis (PF) is a devastating lung disease characterized by excessive extracellular matrix deposition and impaired pulmonary function, with limited therapeutic options. The pathogenesis of PF involves a complex network of molecular events, including epithelial-mesenchymal transition (EMT), activation of fibroblasts, and dysregulated tissue remodeling. Recent studies have identified TRAF2 (TNF receptor-associated factor 2) as a potential modulator of fibrosis, while its precise mechanism remains unclear. Methods: We assessed TRAF2 expression and subcellular localization via immunofluorescence and Western blot. TRAF2 knockdown was achieved through siRNA transfection. Protein and mRNA levels of molecules were detected using wb and RT-qPCR. Molecular interactions (TRAF2/β-catenin/Snail) were validated by co-immunoprecipitation assays. HE staining and Masson staining were quantified. Results: We demonstrate that TRAF2 translocates to the nucleus after fibrosis induction and is positively correlated with disease severity. TRAF2 knockdown significantly reduced collagen deposition and myofibroblast activation, thereby alleviating fibrosis. Furthermore, we investigate the molecular mechanisms by which TRAF2 regulates pulmonary fibrosis, specifically its interaction with β-catenin and Snail, which promotes β-catenin-mediated transcriptional activation and facilitates EMT. These findings offer novel insights into the role of TRAF2 in pulmonary fibrosis, suggesting that TRAF2 may provide a promising therapeutic strategy for this debilitating disease. Discussion: Our study provides valuable insights into the role of TRAF2 in pulmonary fibrosis, while the precise molecular mechanisms by which TRAF2 interacts with β-catenin and Snail in fibrosis remain unclear. Future studies should aim to explore the mechanisms of TRAF2 in more detail, particularly how it interfaces with fibrotic mediators and cellular processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.